Scientists in Germany have made a breakthrough in the development of a nasal vaccine that can prevent Covid-19 from taking hold in the nose and throat. In experiments with hamsters, two doses of the weakened virus resulted in "sterilizing immunity" - essentially eliminating the virus's ability to replicate.
The researchers used a technique called codon pair deoptimization to weaken the genetic material of the virus, making it less capable of causing disease while still eliciting an immune response from the body. This approach is similar to that used in the 1870s for vaccines against anthrax and rabies.
In animal studies, two doses of the nasal vaccine showed a stronger immune response than mRNA-based vaccines or adenovirus-based vaccines. The researchers believe this is because the weakened virus closely mimics the natural infection process, allowing the body to mount a more effective defense.
The new nasal vaccine also has the potential to provide broader protection against different strains of Covid-19, as it previews the entire coronavirus rather than just its spike proteins like current vaccines do.
While promising results have been seen in animal studies, experts caution that further testing is still needed before human trials can begin. The development of a pan-coronavirus vaccine has been stalled due to the rapid evolution of the virus, and the need for a universal vaccine remains a pressing concern.
Several other nasal vaccines are nearing completion in clinical trials, including ones being developed by companies such as Codagenix. While these have shown promise, it's too early to say whether they will ultimately be effective against Covid-19.
One consideration is that live vaccines can pose risks to people with weakened immunity, and therefore must be used carefully. Nevertheless, the idea of a nasal vaccine remains an attractive one, particularly for respiratory infections where inhaled vaccines have struggled to provide adequate protection.
The researchers used a technique called codon pair deoptimization to weaken the genetic material of the virus, making it less capable of causing disease while still eliciting an immune response from the body. This approach is similar to that used in the 1870s for vaccines against anthrax and rabies.
In animal studies, two doses of the nasal vaccine showed a stronger immune response than mRNA-based vaccines or adenovirus-based vaccines. The researchers believe this is because the weakened virus closely mimics the natural infection process, allowing the body to mount a more effective defense.
The new nasal vaccine also has the potential to provide broader protection against different strains of Covid-19, as it previews the entire coronavirus rather than just its spike proteins like current vaccines do.
While promising results have been seen in animal studies, experts caution that further testing is still needed before human trials can begin. The development of a pan-coronavirus vaccine has been stalled due to the rapid evolution of the virus, and the need for a universal vaccine remains a pressing concern.
Several other nasal vaccines are nearing completion in clinical trials, including ones being developed by companies such as Codagenix. While these have shown promise, it's too early to say whether they will ultimately be effective against Covid-19.
One consideration is that live vaccines can pose risks to people with weakened immunity, and therefore must be used carefully. Nevertheless, the idea of a nasal vaccine remains an attractive one, particularly for respiratory infections where inhaled vaccines have struggled to provide adequate protection.